Listen. You may as well sit down. We have a lot to go over.


(NTRB) Is A Low Float Biotech Rocking Big Revenue Growth And A Huge $10 Analyst Target From Zacks SCR

February 14th

SCF Readers,

Listen. You may as well sit down. We have a lot to go over.

First off, we need to take a quick trip down memory lane.

On February 2nd, I delivered a Nasdaq Biotech profile.

That day it opened at $1.13. Fast forward to February 10th... Boom. An astonishing high of $2.65.

134% (approx.) just like that. Solid stuff, but that's not all.

My February 6th profile, an OTCQB Biotech, ran from that day's open of $.319 to a February 9th high of $.5827.

More math? Sure. That's a 4 day run of approximately 82%.

Incredible, right? Two ideas run approximately 216% combined.

But now it's time to turn to a new Nasdaq Biotech breakout idea.

Based on its low float, a price target providing over 100% potential upside, huge revenue growth news, an explosive chart history, and it trading over 3 key lines of potential support, this profile could become a major breakout target early in 2023.

Drop everything and get this Nasdaq idea pulled up right now:

*Nutriband Inc. (NTRB)*

Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse deterrent fent-a-nyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

And based on 5 potential breakout catalysts, NTRB needs full focus right now. Check them out:

No. 1 - Low Float Volatility Could Take Hold At A Moment's Notice

No. 2 - Analyst From Zacks SCR Provides Massive $10 Target

No. 3 - Major Revenue Jump Shows The Potential For An Increasingly Bright Future

No. 4 - A Recent Listing Could Provide Unquantifiable Exposure For NTRB

No. 5 - New Patent Protects AVERSA Transdermal Abuse Deterrent Technology

But more on those in a second...

Nutriband's Lead Product - AVERSA™

The technology is based on the incorporation of taste and sensory aversive agents into the patch.

The aversive agents are formulated in a controlled release matrix that is coated onto the back of a transdermal fent-a-nyl patch. The controlled release aspect of the technology is designed so that the abuse deterrent properties are maintained after normal use and during attempts to separate the aversive agents from the fent-a-nyl.

Nutriband believes that this structure provides maximum exposure during oral abuse and during attempts to extract the drug, while preventing exposure of the patient to the aversive agents during transdermal wear.

The company believes that a key differentiating aspect of the technology is that the aversive agents are physically separated from the drug matrix, meaning that the aversive agents do not have to be formulated in the fent-a-nyl drug matrix and do not contact the skin.

In addition to the fent-a-nyl patch, they believe this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes.

  • AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids
  • Nutriband's lead product is the AVERSA™ abuse deterrent fent-a-nyl transdermal system
  • Upon approval of AVERSA™ fent-a-nyl, we expect that FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics
  • Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate

According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn.

If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$500Mn in revenue.


4P Therapeutics, a clinical subsidiary of Nutriband, should emphasize validating real-world abuse-deterrence which would expand market share and provide more price flexibility.


Aversa is expected to reach peak annual revenues of $76Mn post launch based on a 40% TD fent-a-nyl market share enabled by a 20% price premium from generics.


Grab Sources And More Key Details Here.


And as I mentioned above, NTRB has 5 key potential catalysts to soak in now. Here they are:

No. 1 NTRB Potential Catalyst - Low Float Volatility Could Take Hold At A Moment's Notice

According to the Yahoo Finance website, NTRB has a low float.

The website reports this profile to have approximately 4.18Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could positive company news early this year help provide a near term spark?


No. 2 NTRB Potential Catalyst - Analyst From Zacks SCR Provides Massive $10 Target

Back in October of 2022, M. Marin, an analyst with Zacks Small-Cap Research, provided NTRB with a $10.00 target.

From Monday's closing valuation, that provides NTRB with over 139% potential upside.

Here's some key highlights from the report:


Given NTRB’s steps to expand its operating footprint and protect its IP, we are optimistic about AVERSA’s commercial prospects, as the potential range of applicable uses for the AVERSA technology, the rising incidences of overdose deaths and high related healthcare costs could translate, we believe, into high demand for AVERSA following clinical studies.

We are encouraged by the estimates from Health Advances. We believe in success NTRB could attain annual revenue in the $10Mn to $15Mn range by 2025-26 on its way to achieving scale and peak sales, depending on the commercialization timeline. We believe these forecasts are supported by the growing size of the target markets and AVERSA’s expected ability to improve the safety profile of fent-a-nyl and other prescription medications. Moreover, we also believe that competitive pressure could lead to adoption of the AVERSA technology by several large pharma companies in a short period, if the technology proves as efficient as NTRB believes it will. In fact, fent-a-nyl transdermal patches have become such an important pain therapy that they have been added to the WHO list of essential medicines, as noted, which we believe supports the positive outlook for AVERSA if clinical test results support its efficacy and safety. If the company can maintain its expected timeline and commercialize AVERSA by late 2024, our forecast could prove conservative, depending on several factors.

It is difficult to compare NTRB to other more mature companies, in our view, given the early stage of development of AVERSA and the product portfolio. We would also expect NTRB to have a higher growth rate in the early years. Various other companies that are engaged in introducing new therapies and solutions and are at a similar stage of development have a wide range of price-to revenue multiples on forward estimates. Nevertheless, we believe the average price-to-sales multiple of companies in this comparison of about 14x provides a valuation benchmark for NTRB. Therefore, applying a 14x multiple to our above-noted forecast revenue range and discounting back to the present at 10%/year results in a present value of about $10 to $15 per share on a fully diluted basis, if the company initiates a successful launch of AVERSA. We expect the shares to begin to reflect the low end of this range as it hits certain milestones and incorporate the mid- to high-end as AVERSA development proceeds. Our forecast could change if and when the company expands the number of products leveraging the AVERSA technology.

While there are several risks to the timeline and commercial launch, we think the current share price does not reflect the fundamental value of the company’s pipeline and prospects and would anticipate multiple expansion as the company continues to advance AVERSA. Any delay or failure in clinical development or regulatory approval could cause the share price to decline and represent a potential risk to our valuation but we believe the risk / reward ratio could be attractive for in-vest-ors who have a higher than average risk tolerance and longer time horizon.


No. 3 NTRB Potential Catalyst - Major Revenue Jump Shows The Potential For An Increasingly Bright Future

Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3

ORLANDO, FL / ACCESSWIRE / December 5, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022.

Key Highlights:

  • Generated record quarterly revenue of $620k, up 118% over Q3 2021
  • Revenue for nine-months ended October 31, 2022, was $1.55+Mn, up 67% year-over-year
  • Continued to expand AVERSA™ intellectual property portfolio with patents now issued in 44 countries; AVERSA™ patent coverage includes the U.S., Canada, Europe, Japan, Korea, Mexico, Australia, and Russia, with patents pending in China
  • Demonstrated with Kindeva Drug Delivery enhanced abuse-deterrent characteristics for Aversa Fent-a-nyl
  • Applied for Dual Listing on Upstream
  • St-ockholders' equity of $9.7Mn as of October 31, 2022

"Once again, we have had a record quarter for our revenue generating subsidiaries. Building on these revenue streams remains an important focus for us as we continue to develop AVERSA Fent-a-nyl," commented Gareth Sheridan, CEO of Nutriband. "According to the assessment by Health Advances, AVERSA Fent-a-nyl could reach peak annual sales of between $80 to $200Mn. If the entire transdermal fent-a-nyl market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater. We are continually thankful to our shareholders for their ongoing support as we continue to execute on our vision of commercializing AVERSA.''

Q3 2022 Financial Highlights:

Revenue for the three-months ended October 31, 2022 was $0.6Mn, up 118% from revenue of $0.28Mn in the third quarter of fiscal year 2021. Revenue growth was driven primarily by increasing demand for the Company's Pocono Pharmaceuticals segment.


Read the full article here.


No. 4 NTRB Potential Catalyst - A Recent Listing Could Provide Unquantifiable Exposure For NTRB

Nutriband Inc. Commences Trading on Upstream Under NTRB

Nutriband among the first issuers to dual list on Upstream

ORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".


"We are thrilled to be amongst the first companies to dual list on Upstream's next generation marketplace," says Gareth Sheridan, CEO of Nutriband. "We are adding new value to our shareholders while expanding our company and mission to a modern, global in-vest-or-base."

Read the full article here.


No. 5 NTRB Potential Catalyst - New Patent Protects AVERSA Transdermal Abuse Deterrent Technology

Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent

ORLANDO, FL / ACCESSWIRE / December 1, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022. This patent protects Nutriband's AVERSA™ transdermal abuse deterrent technology being developed to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential that are delivered with a transdermal patch.

The issuance of this Canadian patent in combination with patents already issued in the United States and Mexico provides intellectual property protection for Nutriband's Aversa™ products across North America. In addition, the Aversa™ abuse deterrent technology is covered by a broad intellectual property portfolio with patents already granted in the United States, Europe, Japan, Korea, Russia, and Australia.


Read the full article here.


NTRB Recap - 5 Key Potential Breakout Catalysts For This Nasdaq Idea

No. 1 - Low Float Volatility Could Take Hold At A Moment's Notice

No. 2 - Analyst From Zacks SCR Provides Massive $10 Target

No. 3 - Major Revenue Jump Shows The Potential For An Increasingly Bright Future

No. 4 - A Recent Listing Could Provide Unquantifiable Exposure For NTRB

No. 5 - New Patent Protects AVERSA Transdermal Abuse Deterrent Technology


Coverage is officially initiated on NTRB. To ensure receiving all updates, do this:


Get NTRB on your radar now.


Axel Adams

Editor, SCF

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

SmallCapFirm "SCF" (smallcapfirm . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a license d finan.cial advise r. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: An owner of SWN Media LLC owns and operates fierceinvestor . com (“FI”), owns and operates stockwirenews . com ("SWN"), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. We have not been compensated to disseminate information about (NTRB) in today's profile. We own zero shares of (NTRB). We expect to be compensated sixty thousand USD at a later date and will update disclosures appropriately when it is received.